Stratec Biomedical AG (SBS) Given a €59.00 Price Target by Berenberg Bank Analysts

Berenberg Bank set a €59.00 ($69.41) price objective on Stratec Biomedical AG (ETR:SBS) in a report released on Monday. The firm currently has a neutral rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Warburg Research set a €62.00 ($72.94) target price on shares of Stratec Biomedical AG and gave the company a buy rating in a research note on Tuesday, July 25th. Kepler Capital Markets set a €66.00 ($77.65) target price on shares of Stratec Biomedical AG and gave the company a buy rating in a research note on Wednesday, July 26th. Oddo Securities set a €58.00 ($68.24) target price on shares of Stratec Biomedical AG and gave the company a neutral rating in a research note on Monday, July 24th. Deutsche Bank AG set a €55.00 ($64.71) target price on shares of Stratec Biomedical AG and gave the company a neutral rating in a research note on Thursday, July 27th. Finally, Oddo Bhf set a €58.00 ($68.24) target price on shares of Stratec Biomedical AG and gave the company a neutral rating in a research note on Monday, October 23rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of €60.50 ($71.18).

Shares of Stratec Biomedical AG (SBS) traded up 2.48% during mid-day trading on Monday, hitting €62.50. 665 shares of the stock were exchanged. The company has a market capitalization of €743.00 million and a PE ratio of 38.60. Stratec Biomedical AG has a 12-month low of €41.45 and a 12-month high of €63.18. The firm has a 50-day moving average price of €54.56 and a 200 day moving average price of €55.40.

WARNING: “Stratec Biomedical AG (SBS) Given a €59.00 Price Target by Berenberg Bank Analysts” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/10/31/stratec-biomedical-ag-sbs-given-a-59-00-price-target-by-berenberg-bank-analysts.html.

Stratec Biomedical AG Company Profile

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

What are top analysts saying about Stratec Biomedical AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stratec Biomedical AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit